In this review:
Vismodegib active in basal cell carcinoma
Radium-223 in prostate cancer
Bevacizumab benefits in ovarian cancer
Aflibercept + FOLFIRI: a good second-line therapy
Everolimus + exemestane in advanced breast cancer
Tamoxifen + everolimus improves survival
Please login below to download this issue (PDF)